DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES

Similar documents
Collection of Recorded Radiotherapy Seminars

Hypofractionated radiation therapy for glioblastoma

Radioterapia no Tratamento dos Gliomas de Baixo Grau

Paolo Tini 1,3 M.D. :

Ruolo dell imaging nella pianificazione del trattamento

Oncological Management of Brain Tumours. Anna Maria Shiarli SpR in Clinical Oncology 15 th July 2013

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Alleinige Radiochirurgie und alleinige Systemtherapie zwei «extreme» Entwicklungen in der Behandlung von Hirnmetastasen?

Where are we with radiotherapy for biliary tract cancers?

Partial Breast Irradiation using adaptive MRgRT

Particle Therapy for CNS Tumors Anita Mahajan MD MD Anderson Cancer Center PTCOG, Shanghai June 10, 2014

Carbon Ion Radiotherapy for Skull Base and Paracervical Chordomas

Evaluation of Three-dimensional Conformal Radiotherapy and Intensity Modulated Radiotherapy Techniques in High-Grade Gliomas

PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING

Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed

Advances in external beam radiotherapy

IMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

Role of protons, heavy ions and BNCT in brain tumors

INTRAOPERATIVE RADIATION THERAPY FOR RETROPERITONEAL SARCOMA

Radiation Therapy for Soft Tissue Sarcomas

Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer

Radiotherapy and Brain Metastases. Dr. K Van Beek Radiation-Oncologist BSMO annual Meeting Diegem

Future Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center

Target Delineation in Gliomas. Prof PK Julka Department of Radiotherapy and Oncology AIIMS, New Delhi

Stereotactic radiotherapy

肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部

SBRT in early stage NSCLC

Institute of Oncology & Radiobiology. Havana, Cuba. INOR

NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)

Tecniche Radioterapiche U. Ricardi

MRI Applications in Radiation Oncology:

Description. Section: Therapy Effective Date: July 15, 2015 Subsection: Original Policy Date: September 13, 2012 Subject: Page: 1 of 10

Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience

Radiation Therapy: From Fallacy to Science

UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS

Protons for Head and Neck Cancer. William M Mendenhall, M.D.

Locally advanced head and neck cancer

ES-SCLC Joint Case Conference. Anthony Paravati Adam Yock

Intensity Modulated Radiotherapy (IMRT) for Central Nervous System (CNS) Tumors and Vertebral Tumors

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.

The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans

ART for Cervical Cancer: Dosimetry and Technical Aspects

Sacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician

Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver

Case Conference: SBRT for spinal metastases D A N I E L S I M P S O N M D 3 / 2 7 / 1 2

Hong Kong Hospital Authority Convention 2018

Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study

Clinical Trials for Adult Brain Tumors - the Imaging Perspective

Oral Cavity Cancer Combined modality therapy

Mehmet Ufuk ABACIOĞLU Neolife Medical Center, İstanbul, Turkey

THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD

Glioblastoma: Current Treatment Approach 8/20/2018

Tania Kaprealian, M.D. Assistant Professor UCLA Department of Radiation Oncology August 22, 2015

PROCARBAZINE, lomustine, and vincristine (PCV) is

Oral cavity cancer Post-operative treatment

4/25/2018. Proton Therapy for Head and Neck Cancer: The Future is Now. Disclosures. Overview. Physical limitations of photons

Pre- Versus Post-operative Radiotherapy

Selecting the Optimal Treatment for Brain Metastases

Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT

Hypofractionated Radiotherapy for breast cancer: Updated evidence

Savita Dandapani, MD, PhD City of Hope Duarte, CA

Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展

Hypofractionation in particle therapy. Marco Durante

Demands and Perspectives of Hadron Therapy

Disclosures. The Challenges Facing Proton Beam Therapy and Opportunities. Minesh P Mehta, MBChB, FASTRO

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

Prostate Cancer. 3DCRT vs IMRT : Hasan Murshed

Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors

Implementation of advanced RT Techniques

Radiotherapy for intracranial meningiomas SAMO Interdisciplinary Workshop on Brain Tumors and Metastases November 2016

Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance?

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

What s New in Radiotherapy For STS of The Extremity? Kaled M. Alektiar, MD, FASTRO Dept of Rad Onc Memorial Sloan Kettering Cancer Center

Opportunity for palliative care Research

Hot topics in Radiation Oncology for the Primary Care Providers

Insights into Thymic Epithelial Tumors: Radiation Therapy

Optimal Management of Isolated HER2+ve Brain Metastases

Antiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

Protocol of Radiotherapy for Head and Neck Cancer

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

NRG Oncology Lung Cancer Portfolio 2016

External Beam Radiotherapy for Prostate Cancer

Radiotherapy for rectal cancer. Karin Haustermans Department of Radiation Oncology

Locally advanced disease & challenges in management

Status of H 1 and C 12

Clinical Study Hypofractionated High-Dose Irradiation with Positron Emission Tomography Data for the Treatment of Glioblastoma Multiforme

THE TRANSITION FROM 2D TO 3D AND TO IMRT - RATIONALE AND CRITICAL ELEMENTS

Defining Target Volumes and Organs at Risk: a common language

Clinical experience with TomoDirect System Tangential Mode

성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)

Clinical Implications Of Dose Summation And Adaptation

Linac Based SBRT for Low-intermediate Risk Prostate Cancer in 5 Fractions: Preliminary Report of a Phase II Study with FFF Delivery

Stereotactic Radiosurgery for Brain Metastasis: Changing Treatment Paradigms. Overall Clinical Significance 8/3/13

Report on Radiation Disaster Recovery Studies

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer

Transcription:

DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro

THE STANDARD OF CARE Stupp R 2005 3D conformal RT (TD = 60 Gy, 2Gy / fx): CTV: GTV plus 2-3 cm margin Planning on CT images No analysis of the pattern of recurrence

Minniti et al, 2010 105 pts with GBM 105 3D-CRT Pts, planning & TMZ: on 60 CT-MRI Gy fr 2 Gy/die (EORTC Guidelines) Postoperative MRI scans were fused with the planning CT images in Recurrence each patient. : GTV : resection cavity and any residual tumor as seen on a c.e. T1 postoperative central in MRI. 79 pts 75% CTV1: GTV plus 2-cm margins. EORTC guidelines80.7% in-field in 6 pts 5.7% For CTV more than 250 cm3 the prescribed dose was 50 Gy in 25 marginal in 6 pts 5.7% of outside 10 Gy in 5 in fractions. 14 pts 13% fractions to the CTV, and a boost to the GTV plus 1-cm margin (CTV2) The CTV margins were reduced to 0.5 cm around natural barriers to tumor growth (the skull, ventricles, falx, etc.), and also to allow sparing of the optic nerve/chiasm, if necessary. Central/in-field recurrence: 64% of MGMT methylated pts PTV1 and PTV2 : CTVs plus 0.3 91% cmof MGMT unmethylated pts

GBM- Dose escalation

ARCON IN GLIOBLASTOMA (EORTC 22933), Miralbell, JCO, 1999 Pts: 115 (23 ARCO, 28 ARN, 56 ARCON) Dose: 60 Gy Bid (1.5 x 2) Median survival: 10.1 months ARCO 9.7 months ARN 11.1 months ARCON Main toxicity: gastrointestinal (Nicotinamide)

Rationale Dose intensification Shorter treatment time Less cell repopulation Less influence of shoulder in cell survival curves Better quality of life Curran W, in The Gliomas, 1999 Glinski B, Journal of Neuro-Oncology, 1993 Sayin M. Y, Medical Oncology, 2007 Hulshof MCCM, Radiotherapy and Oncology, 2000

The NORDIC TRIAL A. Malmstrom, Lancet Oncology 2012 Histological 119 pattern: pts Glioblastoma multiforme (WHO IV) Age> 60 yrs 342 pts RT enrolled 60 Gy (2000 Gy x 30) 2009) 342 pts Newly diagnosed GBM 100 pts Age: RT 6034 years Gy (3.4 Gy x 10) 123 pts TMZ x 6 (200 mg/m 2 d 1-5 q 28 d)

RESULTS: Standard RT 60 Gy was in no case superior to RT 34 Gy or TMZ alone Both TMZ and hypofractionated RT should be considered as standard treatment options in elderly patients with GBM All pts Pts age 60-70 yrs Pts age > 70 yrs

Iuchi, et al; IJROBP,2006 25 pts; HGG (2 AA & 23 GBM), median age 60; IMRT PTV-1 = enhanced lesion with 5-mm margin PTV-2 = area with 15-mm margin surrounding the PTV-1 PTV-3 = area of perifocal edema. IMRT in 8 fxs: dose for PTV-1 was escalated from 48 Gy to 68 Gy while maintaining dose for PTV-2 (40 Gy) and PTV-3 (32 Gy). Outcome of IMRT was compared with 60 HGG treated by conventional RT

IMRT Dose escalation The effect of dose-escalation on local control (a) and patients survival (b). BED<72 Gy= 60Gy With conventional fx Iuchi, et al; IJROBP,2006

Stereotactic radiosurgery Binello E, Surgical Neurology International, Review 2012

Nwokedi E.C, Neurosurgery 2002 31 pts with GBM median prescribed EBRT dose was 59.7 Gy OS 25 m (range, 45 70.2 Gy) with fractionation of 1.8 to 2.0 Gy/d. Planned GK-SRS boost (17.1 Gy) within 4 weeksos after 13 mebrt Planning on MRI 33 pts in the group who underwent EBRT only

How to improve RT dose delivery? IMRT - IGRT

R&O 2010 3D-CRT and IMRT techniques provide similar results in terms of target coverage; IMRT is better than 3D-CRT in reducing the maximum dose to the organs at risk, although to an extent that varies considerably from case to case; IMRT is clearly better than 3D-CRT in terms of dose conformality and sparing of the healthy brain tissue at medium to low doses; There is no case in which IMRT seems to be worse than 3DCRT, From the dosimetric point of view, IMRT appears adequate for the treatment of GBM. In GBM patients with good prognosis, SIB IMRT allows to deliver hypofractionated regimens that, in association with CHT, suggests the possibility to achieve results that are even superior to those obtainable by the standard treatment.

Chen L, Johns Hopkins University, IJROBP 2013 A putative source of glioma stem cells is the subventricular zone (SVZ), the largest area of neurogenesis in the adult human brain. Multipotent neural progenitor cells (NPCs) line the lateral wall of the lateral ventricles (LVs). To analyse the relationship between RT dose to the SVZ and patient outcome (DFS and OS)

SVZ & RADIATION DOSE 116 GBM pts 41 GTR IMRT PFS & OS in patients whose ipsilateral subventricular zone (SVZ) received > 40 Gywere significantly different from that in pts who received a dose of > 40 Gy 15.1 months 17.5 months 10.3 months 15.6 months

PTV2 PTV1 IMRT p+ active p+ passive C ions (Krengli et al, ASTRO, 2006)

PROTONTHERAPY IN GBM (Fitzek, MGH-HCL, 1999) Fx: b.i.d. (1.8 GyE x 2), 50 fxs, 5 wks 3 volumes: V1 (90 GyE), V2 (64.8 GyE), V3 (50.4 GyE) Tumor progression: 16/23 (1 in 90 GyE volume) Tumor progression: 16/23 (1 in 90 GyE vol.) Toxicity: necrosis in all 23 pts Open issue: Identification of target volume?

Carbon ions and Angiogenesis Comparison of 290 MeV carbon ion beam and photons Carbon ions are able to inhibit angiogenic factors like matrix metalloproteinese-2 even at subclinical doses (0.1 GyE) Effects of irradiation on the formation of capillary-like tube structures assessed in a collagen-embedded culture. Takahashi, Cancer Res, 2003

Results Prolungation of OS with higher doses No grade 3-4 acute and late toxicity and no evidence of dose toxicity correlation Mizoe et al., IJROBP, 2007

GBM AA They projected the potential increase in outcome when combined C12 and TMZ would have been applied. A generated hypothetical curve based on the above mentioned outcome suggests there might be a benefit from the addition of C12 in patients with high-grade gliomas.

Protocol for GBM @ CNAO (to be activated) Total dose: 74 Gy[RBE], 2 Gy[RBE]/fx Assessment: acute toxicity, local response, DFS, OS, late toxicity

NCCN Guidelines Version 2.2013 PRINCIPLES OF BRAIN TUMOR RADIATION THERAPY High Grade Gliomas (Grades III/IV) The gross tumor volume (GTV) is best defined using preand postoperative MRI imaging using enhanced T1 and FLAIR/T2. The GTV is expanded by 2-3 cm (CTV) to account for sub-diagnostic tumor infiltration. Fields are usually reduced for the last phase of the treatment (boost).

(Price, Eur Radiol 2007) Decreased anisotropy (q) = gross tumor margin Increased isotropy (p) = infiltrating tumor margin

Can imaging by PW and DW MR help in identification of radiation target? 17 pts: 14 M, 3 F surgery+rt (60 Gy) + TMZ Timing of image acquisition: MR DWI and MR PWI pre RT (T0) MR DWI and MR PWI after RT (2 months) and during F/U (every 4 months) @ PD: MR DWI and MR PWI (T1) MR DWI @ T1 MR PWI @ T1 (Stecco et al, J Neurooncol, 2011)

Retrospective study on marginal recurrence with MET-PET 26 pts, GTV contoured with MRI, 5 had MET enhancement outside GTV; 5/5 marginal recurrences when the area MET+ was not included in the GTV vs. 2/21 in the others. Lee et al. IJROBP 2009

Einstein DB, IJROBP 2012 35 patients with surgical resection or biopsy The RT treatment: mediansrs survival directedwas toward15.8 areasmonths. of MRS-determined high biological activity within 2 cm of the postoperative enhancing surgical bed. For the 16 /35 pts who received concurrent TMZ, the median survival was 20.8 months (historical controls of 14.6 months). The treatment is feasible, with acceptable toxicity and patient survivals higher than in historical controls.

Medical Dosimetry 2008 To study the feasibility of incorporating functional fmri information for IMRT treatment planning of brain tumors. Three glioma patients wereconclusion: retrospectively replanned for radiotherapy (RT) with additional fmri information. IMRT can reduce the RT dose to the primary motor cortex (PMC) without compromising the PTV coverage or sparing of other critical organs. IMRT planning allows a significant reduction in RT dose to the PMC regions.

Does technique/dose/fractionation matter in Clinical Practice? Technique: IMRT may be better than CT at least in selected cases Imaging: need for MRI in planning (T1 and T2 flair) Dose/Fractionation: Hypofractionation preserves QoL in pts with worse prognosis

Does technique/dose/fractionation matter in Clinical Trials? Technique: Highly sophisticated techniques, IMRT (SRT), protons, ions, have the potential to improve results. Treatment volume defined on biological and not only morphological data showed a potential improvement of results. Dose: Higher doses also with high-let radiations showed promising results and sould be explored further. Fractionation: Different dose per fraction also by SIB and LET-painting are also very promising. Identification of patients who my benefit from more aggressive treatments (age, PS, MGMT, IDH1-2, EGFR)